PHESGO

Phase 3Small molecule

Roche

PHESGO is one of 45 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Metastatic Breast CancerRecruiting

Breast CancerPhase 2

Active, not recruiting

Metastatic Breast CancerPhase 3

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

PHESGO

Roche

Phase 3

4 2

Tecentriq

Roche

Preclinical

36 3

Spravato

WWim Janssens

Preclinical

2 4

Chirocaine

PPurdue Pharma LP

Preclinical

1 5

Nubain

AAultman Health Foundation

Preclinical

1 6

Acupan

YYonsei University

Preclinical

1 7

Aquasol E

NNational Eye Institute (NEI)

Systemic Therapy

1 9

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 10

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Breast Cancer

NCT05306041

Q4 2030

Phase 3Active, not recruiting

Breast Cancer

NCT05296798

Q2 2032

Phase 2Active, not recruiting

Breast Cancer

NCT06068985

Q4 2032

Phase 3Recruiting

Metastatic Breast Cancer

NCT05894239

Clinical

Trials by Indication[1]

Breast Cancer4 trials

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05296798·922 enrolled

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

Active, not recruiting·LLatin American Cooperative Oncology Group·Phase 2·NCT06068985·63 enrolled

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Recruiting·—·Phase 2·NCT06439693·72 enrolled

Show 1 more trial

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Recruiting·GGBG Forschungs GmbH·Phase 2·NCT05306041·170 enrolled

Metastatic Breast Cancer1 trial

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Recruiting· Roche logo

Roche·Phase 3·NCT05894239·230 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 29, 2020

PHESGO

BLA BLA761170

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for PHESGO. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PHESGO compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PHESGO. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761170). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

PHESGO

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2030

Q2 2032

Q4 2032

Trials by Indication[1]

Breast Cancer4 trials

Metastatic Breast Cancer1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News